Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12606000520538
Ethics application status
Approved
Date submitted
12/12/2006
Date registered
18/12/2006
Date last updated
13/07/2010
Type of registration
Retrospectively registered
Titles & IDs
Public title
Phase I accelerated dose-escalation study of CYT997 given as an oral capsule every two weeks in patients with advanced solid tumours
Query!
Scientific title
Phase I accelerated dose-escalation study to determine the safety and tolerability of CYT997 when given as an oral capsule every two weeks in patients with advanced solid tumours
Query!
Secondary ID [1]
252204
0
CCL06001
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Cancer - solid malignancies that are metastatic or unresectable
1495
0
Query!
Condition category
Condition code
Cancer
1592
1592
0
0
Query!
Other cancer types
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
CYT997 administered as an oral capsule dose on a two weekly cycle for up to six cycles. The starting dose is 15mg/m2 and the dose escalates at 1.4x the previous dose. Dose escalation may occur every two weeks (ie at the completion of the first cycle for each successive patient in the dose-escalation phase). Dose-escalation will cease at the occurrence of drug-related Grade 4 neutropenia lasting 5 days or longer or associated with fever requiring antibiotics; Grade 4 thrombocytopenia or non-haematological toxicity of Grade 3 or greater (excluding nausea, vomiting and diarrhoea with optimal treatment).
Query!
Intervention code [1]
1502
0
Treatment: Drugs
Query!
Comparator / control treatment
No comparator.
Query!
Control group
Uncontrolled
Query!
Outcomes
Primary outcome [1]
2196
0
To establish the dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) of CYT997 following oral administration. For an adverse event to qualify as a dose-limiting toxicity it must occur in the first cycle of therapy (for each patient). Dose-escalation ceases when an adverse event which qualifies as a DLT occure in the first cycle of a given dose level and, in accordance with the protocol, further patients are enrolled at this dose level until the sooner of a second DLT or 6 patients are enrolled in total. When a second DLT does occur, no further patients are enrolled at this dose and the MTD is determined. Further patients may be enrolled at the previous dose level to define the recommended dose for Phase II studies.
Query!
Assessment method [1]
2196
0
Query!
Timepoint [1]
2196
0
DLTs are assessed throughout the first cycle and the MTD is determined when two or more DLTs occur at a particular dose level.
Query!
Secondary outcome [1]
3826
0
(i) To study the pharmacokinetics of CYT997 following oral administration
Query!
Assessment method [1]
3826
0
Query!
Timepoint [1]
3826
0
After dose administration in the first and second cycles
Query!
Secondary outcome [2]
3827
0
(ii) To characterise the toxicities and tolerability of CYT997 following oral administration
Query!
Assessment method [2]
3827
0
Query!
Timepoint [2]
3827
0
Continuously throughout the study
Query!
Secondary outcome [3]
3828
0
(iii) To define a recommended dose for oral Phase II studies
Query!
Assessment method [3]
3828
0
Query!
Timepoint [3]
3828
0
Following determination of the MTD
Query!
Secondary outcome [4]
3829
0
(iv) To make a preliminary evaluation of anti-tumour activity
Query!
Assessment method [4]
3829
0
Query!
Timepoint [4]
3829
0
After every second cycle of drug
Query!
Secondary outcome [5]
3830
0
(v) To make a preliminary evaluation of vascular-targetting activity
Query!
Assessment method [5]
3830
0
Query!
Timepoint [5]
3830
0
From data acquired during the first cycle
Query!
Secondary outcome [6]
3831
0
(vi) To assess pharmacokinetic/pharmacodynamic relationships
Query!
Assessment method [6]
3831
0
Query!
Timepoint [6]
3831
0
From data collected in the first cycle
Query!
Eligibility
Key inclusion criteria
(i) Confirmed solid malignancy; (ii) Life-expectancy of greater than 3 months; (iii) No anticancer chemotherapy or hormonal therapy for the preceding 4 weeks; (iv) Adequate organ and marrow function.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
Not stated
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
(i) Patients must not have received other experimental agents in preceding 4 weeks; (ii) Known brain metastases; (iii) Patients with various cardiovascular risk factors are excluded; (iv) Pregnancy and immune deficiency.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Safety
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Date of first participant enrolment
Anticipated
12/12/2006
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
15
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
VIC,QLD,SA
Query!
Funding & Sponsors
Funding source category [1]
1737
0
Commercial sector/Industry
Query!
Name [1]
1737
0
Cytopia Research Pty Ltd
Query!
Address [1]
1737
0
576 Swan St, Richmond, Victoria, 3121.
Query!
Country [1]
1737
0
Australia
Query!
Primary sponsor type
Commercial sector/Industry
Query!
Name
Cytopia Research Pty Ltd
Query!
Address
576 Swan St, Richmond, Victoria, 3121.
Query!
Country
Australia
Query!
Secondary sponsor category [1]
1532
0
None
Query!
Name [1]
1532
0
Nil
Query!
Address [1]
1532
0
Query!
Country [1]
1532
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
3214
0
Department of Medical Oncology Royal Brisbane and Women's Hospital
Query!
Ethics committee address [1]
3214
0
Butterfield St, Herston, Qld.
Query!
Ethics committee country [1]
3214
0
Australia
Query!
Date submitted for ethics approval [1]
3214
0
Query!
Approval date [1]
3214
0
06/12/2006
Query!
Ethics approval number [1]
3214
0
2006/147
Query!
Ethics committee name [2]
3215
0
Q-Pharm Pty Ltd-Queensland Institute of Medical Research HREC
Query!
Ethics committee address [2]
3215
0
300C Herston Road Herston, Qld.
Query!
Ethics committee country [2]
3215
0
Australia
Query!
Date submitted for ethics approval [2]
3215
0
Query!
Approval date [2]
3215
0
13/10/2006
Query!
Ethics approval number [2]
3215
0
H0610-047T (P1035)
Query!
Ethics committee name [3]
5966
0
Southern Health Human Research Ethics Committee
Query!
Ethics committee address [3]
5966
0
Monash Medical Centre
246 Clayton Road
Clayton Victoria 3168
Query!
Ethics committee country [3]
5966
0
Australia
Query!
Date submitted for ethics approval [3]
5966
0
23/05/2008
Query!
Approval date [3]
5966
0
01/09/2008
Query!
Ethics approval number [3]
5966
0
08002A
Query!
Ethics committee name [4]
5969
0
Bellberry Human Research Ethics Committee
Query!
Ethics committee address [4]
5969
0
1st Floor, 71 Anzac Highway, Ashford, South Australia, 5035
Query!
Ethics committee country [4]
5969
0
Australia
Query!
Date submitted for ethics approval [4]
5969
0
01/03/2008
Query!
Approval date [4]
5969
0
07/04/2008
Query!
Ethics approval number [4]
5969
0
New ethics HREC. Please modify.
Query!
Summary
Brief summary
This is a study of an experimental oral anti-cancer drug called CYT997, given every two weeks, to people with advanced cancer.
You may be eligible to join this study if you have an advanced solid tumour cancer and a life expectancy of more than three months.
CYT997 is an experimental anti-cancer agent which targets the blood supply to the tumour. Participants will receive CYT997 as an oral capsule dose on a two weekly cycle for up to six cycles.
Most advanced cancers will eventually stop responding to cancer treatments. In this situation, for people who may be eligible for this drug trial, there may not be any alternative standard treatments. Participants will receive supportive care and symptomatic treatments during the trial, in addition to receiving CYT997.
The major focus of this trial is to test the safety of CYT997 when given orally every 2 weeks. The trial also aims to assess the effect (good and bad) that CYT997 may have on you and your cancer. This involves finding out the highest dose of CYT997 that can be given without causing severe side effects.
This is a study of an experimental oral anti-cancer drug called CYT997, given every two weeks, to people with advanced cancer.
You may be eligible to join this study if you have any sort of solid cancer and a life expectancy of greater than three months.
Participants receive oral capsules of CYT997, which is an experimental anti-cancer agent which targets the blood supply to the cancer. This trial aims to determine the safety and tolerability of CYT997 when given as an oral capsule dose on a two weekly cycle for up to six cycles.
Most advanced cancers will eventually stop responding to cancer treatments. In this situation, there may not be an alternate standard treatment for people who may be suitable for this drug trial. Participants will receive supportive care and symptomatic treatments during the trial in addition to CYT997. This trial aims to find a maximum safe dose, and determine any side effects of CYT997 given orally every 2 weeks.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
27436
0
Query!
Address
27436
0
Query!
Country
27436
0
Query!
Phone
27436
0
Query!
Fax
27436
0
Query!
Email
27436
0
Query!
Contact person for public queries
Name
10691
0
Dr Gregg Smith
Query!
Address
10691
0
576 Swan St, Richmond, Victoria, 3121.
Query!
Country
10691
0
Australia
Query!
Phone
10691
0
+61 3 9208 4222
Query!
Fax
10691
0
Query!
Email
10691
0
[email protected]
Query!
Contact person for scientific queries
Name
1619
0
Dr Gregg Smith
Query!
Address
1619
0
576 Swan St, Richmond, Victoria, 3121.
Query!
Country
1619
0
Australia
Query!
Phone
1619
0
+61 3 9208 4222
Query!
Fax
1619
0
+61 3 9208 4299
Query!
Email
1619
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF